Heart failure (HF) is a progressive disease characterized by variable durations of
symptomatic stability often punctuated by episodes of worsening despite continued therapy …

Cardiovascular disease (CVD) remains the leading cause of death for both women and men
worldwide. In the United States (US), there are significant disparities in cardiovascular risk …

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure with preserved ejection fraction, but additional data …

Episodes of worsening symptoms and signs characterize the clinical course of patients with
chronic heart failure (HF). These events are associated with poorer quality of life, increased …

Hospital at home (HaH) is an innovative care model that may be particularly suited for heart
failure (HF). Outpatient visits and inpatient care have been the 2 traditional settings for HF …

Importance The US Food and Drug Administration (FDA) expanded labeling for
sacubitril/valsartan for use in individuals with chronic heart failure (HF) with left ventricular …

BACKGROUND: Hospitalization is recognized as a sentinel event in the disease trajectory of
patients with heart failure (HF), but not all patients experiencing clinical decompensation are …

Importance In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved
Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first …

Background: Neighborhood socioeconomic status (SES) is associated with worse health
outcomes, yet its relationship with in-hospital heart failure (HF) outcomes and quality metrics …

Over the last two decades, the changing paradigm of heart failure with preserved ejection
fraction (HFpEF) has transformed our understanding not only of the pathophysiology of this …